Author: Publisher:
ISBN:
Category : Analytical chemistry
Languages : de
Pages : 528
Book Description
Helvetica Chimica Acta
Author: Publisher:
ISBN:
Category : Analytical chemistry
Languages : de
Pages : 528
Book Description
Helvetica chimica acta
Author: Highlights of Chemistry
Author: Mehmet Volkan KısakürekPublisher: Helvetica Chimica ACTA
ISBN: 9783906390086
Category : Chemistry
Languages : de
Pages : 985
Book Description
Highlights of Chemistry
Author: M. Volkan KisakürekPublisher: Wiley-VCH
ISBN:
Category : Science
Languages : de
Pages : 1002
Book Description
This book provides a comprehensive overview of more than 75 years of Swiss chemical research. Leading authors, among them L. M. Venanzi, H. Zollinger, E. Heilbronner and J. D. Dunitz, highlight outstanding pieces of research that have appeared in Helvetica Chimica Acta since its foundation, in 1917. This collection of highly readable essays will be of great interest to chemists, historians of chemical science, and anyone who wants to know more about the exciting development of Swiss chemistry in the twentieth century.
Helvetica Chimica Acta
Author: Proceedings
Author: Walter Schneider (Dr. chem., Zürich)Publisher:
ISBN:
Category : Chemistry, Physical and theoretical
Languages : de
Pages : 532
Book Description
Handbook of Asymmetric Heterogeneous Catalysis
Author: Kuiling DingPublisher: John Wiley & Sons
ISBN: 3527319131
Category : Science
Languages : en
Pages : 467
Book Description
In this most up-to-date handbook each chapter contains a general introduction, followed by the principles of the immobilization and, finally, applications. In this way, it covers the most important approaches currently employed for the heterogenization of chiral catalysts, including data tables, applications, reaction types and literature citations. For chemists in both academia and industry as well as those working in the fine chemical and pharmaceutical industry.
Cisplatin
Author: Bernhard LippertPublisher: John Wiley & Sons
ISBN: 9783906390208
Category : Medical
Languages : en
Pages : 628
Book Description
30 years after its discovery as an antitumor agent, cisplatin represents today one of the most successful drugs in chemotherapy. This book is intended to reminisce this event, to take inventory, and to point out new lines of development in this field. Divided in 6 sections and 22 chapters, the book provides an up-to-date account on topics such as - the chemistry and biochemistry of cisplatin, - the clinical status of Pt anticancer drugs, - the impact of cisplatin on inorganic and coordination chemistry, - new developments in drug design, testing and delivery. It also includes a chapter describing the historical development of the discovery of cisplatin. The ultimate question - How does cisplatin kill a cell? - is yet to be answered, but there are now new links suggesting how Pt binding to DNA may trigger a cascade of cellular reactions that eventually result in apoptosis. p53 and a series of damage recognition proteins of the HMG-domain family appear to be involved. The book addresses the problem of mutagenicity of Pt drugs and raises the question of the possible relevance of the minor DNA adducts, e.g. of interstrand cross-links, and the possible use of trans-(NH3)2Pt(II)-modified oligonucleotides in antisense and antigene strategies. Our present understanding of reactions of cisplatin with DNA is based upon numerous model studies (from isolated model nucleobases to short DNA fragments) and application of a large body of spectroscopic and other physico-chemical techniques. Thanks to these efforts there is presently no other metal ion whose reactions with nucleic acids are better understood than Pt. In a series of chapters, basic studies on the interactions of Pt electrophiles with nucleobases, oligonucleotides, DNA, amino acids, peptides and proteins are reported, which use, among others, sophisticated NMR techniques or X-ray crystallography, to get remarkable understanding of details on such reactions. Reactivity of cisplatin, once bound to DNA and formerly believed to be inert enough to stay, is an emerging phenomenon. It has (not yet) widely been studied but is potentially extremely important. Medicinal bioinorganic chemistry - the role of metal compounds in medicine - has received an enormous boost from cisplatin, and so has bioinorganic chemistry as a whole. There is hardly a better example than cisplatin to demonstrate what bioinorganic chemistry is all about: The marriage between classic inorganic (coordination) chemistry and the other life sciences - medicine, pharmacy, biology, biochemistry. Cisplatin has left its mark also on areas that are generally considered largely inorganic. The subject of mixed-valance Pt compounds is an example: From the sleeping beauty it made its way to the headlines of scientific journals, thanks to a class of novel Pt antitumor agents, the so-called "platinum pyrimidine blues". In the aftermath diplatinum (III) compounds were recognized and studies in large numbers, and now an organometalic chemistry of these diplatinum (III) species is beginning to emerge. The final section of the book is concerned with new developments such as novel di- and trinuclear Pt(II) drugs with DNA binding properties different from those of cisplatin, with orally active Pt(IV) drugs which are presently in clinical studies, and with attempts to modify combinatorial chemistry in such a way that it may become applicable to fast screening of Pt antitumor drugs. The potential of including computational methods in solving questions of Pt-DNA interactions is critically dealt with in the concluding chapter.
Author: Christoph Herm
Author: